Clinical trials: Acute Phase
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00918333
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Mayo Clinic
Vitamin D Deficiency, Stem Cell Transplant Complications
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Research has suggested that children with sufficient vitamin D levels undergoing hematopoietic stem cell transplant (HSCT) have improved outcomes, including lower incidences of infection and graft-versus-host disease (GVHD), as…
- Conditions
- Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder
- Trial name
- NCT03176849
- Testing
- Vitamin D3, Standard Vitamin D3 Supplementation
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Phoenix Children's Hospital
Graft Versus Host Disease, Leukemia
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, together with antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00740467
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Paoli-Calmettes
Acute Myeloid Leukemia
Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia
The prognosis of elderly patients with relapsed or refractory acute myeloid leukemia (AML) is grave. Because of their chronological age and/or the presence of multiple co-morbidities, treatment-related mortality in elderly…
- Trial name
- NCT01039363
- Testing
- Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Samsung Medical Center
Duodenal Ulcer
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)
Patients with endoscopically diagnosed active duodenal ulcer disease were enrolled in a randomized, double-blind, parallel and positive-controlled trial.
- Trial name
- NCT00952978
- Testing
- 10 mg ilaprazole, 20 mg omeprazole
- Where
- China
- Volunteers
- 496 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Infection With Coronavirus SARS-CoV2
Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation
Infection with coronavirus SARS-CoV2 (COVID-19 disease) is unique with its speed of propagation, structural medical reorganizations and length of stay in intensive care needed, diversity of the affected population (in particular…
- Trial name
- CAPACoV19 (NCT04356378)
- Testing
- Data record
- Where
- France
- Volunteers
- 149 people
- Sponsor
- CHU de Reims
Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
- Trial name
- P2_ABSSSI (NCT03964493)
- Testing
- TNP-2092, Vancomycin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- TenNor Therapeutics Limited
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Study Design: This is a two-stage Phase II trial investigating the efficacy of Clofarabine, Cyclophosphamide and Etoposide in acute leukemia patients with detectable minimal residual disease (MRD) prior to allo-HCT.
- Trial name
- NCT01677949
- Testing
- Clofarabine, Etoposide, Cyclophosphamide
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
This is a multi-center, open-label, single-arm, phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of mitoxantrone hydrochloride liposome injection in subjects with acute myeloid leukemia (AML).
- Trial name
- NCT05345938
- Testing
- Mitoxantrone Hydrochloride Liposome
- Where
- China
- Volunteers
- 1 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Newly Diagnosed Acute Myeloid Leukemia With High Risk
HVA vs IA/DA or VA in the Treatment of ND HR-AML
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed…
- Trial name
- NCT06810791
- Testing
- HVA, VA, Standard Chemotherapy
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Ischemic Stroke, Carotid Stenosis
STAND: iSchemic sTroke evAluated at Bed Side With ultrasouND
Ischemic strokes account for more than 80% of strokes. Ischemic strokes are caused by the occlusion of an intracranial artery by a thrombus, responsible for tissue ischemia related to a decrease in local cerebral blood flow…
- Trial name
- STAND (NCT04180826)
- Testing
- Observational
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Endocarditis, Bacterial
IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis
Patients with definite or possible infective endocarditis are included in this protocol, at the acute phase of the disease.
- Trial name
- IMAGE (NCT00144885)
- Testing
- Modification of therapy
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stroke
Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)
The purpose of this study was to explore trends in safety and efficacy, and to find the optimal dose for the subsequent phase III trial.
- Trial name
- DEDAS (NCT00638248)
- Testing
- Desmoteplase
- Volunteers
- 38 people
- Sponsor
- PAION Deutschland GmbH
Acute Myeloid Leukemia
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
The purpose of this study is to assess the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in a cohort of Japanese participants ≥ 55 years of age with Acute…
- Trial name
- NCT05197426
- Testing
- Oral Azacitidine
- Where
- 31 sites in United States, Japan
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myelogenous Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
This study will evaluate MK0457 in combination with Dasatinib in patients with Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Efficacy and Safety will be evaluated.
- Trial name
- NCT00500006
- Testing
- MK0457, dasatinib
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Impairment of Gastric Emptying, Acute Phase of Myocardial Infarction
Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.
Oral antiplatelet therapy is a key treatment of the STEMI (ST elevation myocardial infarction). Delayed action isn't suitable and has to be elucidated.
- Trial name
- GASTRIM (NCT02251249)
- Testing
- Paracetamol concentration time curve from 0 to 120 min
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Bordeaux
Ischemic Stroke
A Phase Ib/II in Patients With Acute Ischemic Stroke
Stroke is the fifth leading cause of death in the United States and is the leading cause of long term disability. Distinct geographic disparities in stroke mortality, with highest rates in the southeast United States including…
- Trial name
- NCT02963376
- Testing
- 0.05 mL/kg DDFPe, 0.10 mL/kg DDFPe, 0.17 mL/kg DDFPe
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NuvOx LLC
CD19 Positive, CD22 Positive
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia…
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease
- Trial name
- NCT04029038
- Testing
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Aortic Dissection
Hemodynamic Changes in the Aorta After Endovascular Treatment of the Aortic Dissection
Aortic dissection (AD) is a serious pathology affecting one person for 300 000 habitants per year. In case of complicated AD on the descending aorta, it is necessary to perform an endovascular surgery in association with medical…
- Trial name
- 4DAo (NCT03669055)
- Testing
- Magnetic Resonance Imaging
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
Acute Promyelocytic Leukemia
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.
- Trial name
- NCT00670150
- Testing
- NRX 195183 (retinoid analogue), Arsenic Trioxide
- Where
- United States
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.